PURPOSE: The aim of the study was to develop a rapid and reproducible method to label LY2181308, an antisense oligonucleotide to Survivin, with carbon-11 in order to study its in vivo biodistribution and tumor uptake in rodents and its human dosimetry based on baboon data. METHODS: Randomly [¹¹C] methylated LY2181308 was produced with [¹¹C] methyl iodide. The biodistribution was performed in female Sprague-Dawley (SD) rats and EMT-6 tumor-bearing mice in the presence of nonradioactive LY2181308. Human dosimetry calculations were based on baboon PET studies. RESULTS: In SD rats, the kidney and liver were the organs with the most accumulation of radioactivity. Tumor uptake in mice was also relatively high after 5 min and remained constant for up to 1 h. Baboon dosimetry suggested that up to 42 mCi of radioactivity could be administered to human with a dose-limiting organ being the kidneys with a radiation dose of 32 µGy/MBq (0.118 rad/mCi). CONCLUSIONS: [¹¹C] methylated LY2181308 to rodents and baboons showed its biodistribution, tumor uptake, and human dosimetry evaluation. These results should facilitate the understanding of the pharmacokinetics of LY2181308 prior to use as a potential new therapeutic agent in oncology as well as to warrant more in vivo validations as a potentially useful tumor-imaging agent.
PURPOSE: The aim of the study was to develop a rapid and reproducible method to label LY2181308, an antisense oligonucleotide to Survivin, with carbon-11 in order to study its in vivo biodistribution and tumor uptake in rodents and its human dosimetry based on baboon data. METHODS: Randomly [¹¹C] methylated LY2181308 was produced with [¹¹C] methyl iodide. The biodistribution was performed in female Sprague-Dawley (SD) rats and EMT-6 tumor-bearing mice in the presence of nonradioactive LY2181308. Human dosimetry calculations were based on baboon PET studies. RESULTS: In SD rats, the kidney and liver were the organs with the most accumulation of radioactivity. Tumor uptake in mice was also relatively high after 5 min and remained constant for up to 1 h. Baboon dosimetry suggested that up to 42 mCi of radioactivity could be administered to human with a dose-limiting organ being the kidneys with a radiation dose of 32 µGy/MBq (0.118 rad/mCi). CONCLUSIONS: [¹¹C] methylated LY2181308 to rodents and baboons showed its biodistribution, tumor uptake, and human dosimetry evaluation. These results should facilitate the understanding of the pharmacokinetics of LY2181308 prior to use as a potential new therapeutic agent in oncology as well as to warrant more in vivo validations as a potentially useful tumor-imaging agent.
Authors: Doo Min Sohn; Sung Yong Kim; Moo Jun Baek; Cheol Wan Lim; Min Hyuk Lee; Moo Sik Cho; Tae Yoon Kim Journal: Biomed Pharmacother Date: 2006-06-23 Impact factor: 6.529
Authors: B Tavitian; S Terrazzino; B Kühnast; S Marzabal; O Stettler; F Dollé; J R Deverre; A Jobert; F Hinnen; B Bendriem; C Crouzel; L Di Giamberardino Journal: Nat Med Date: 1998-04 Impact factor: 53.440
Authors: R A Olie; A P Simões-Wüst; B Baumann; S H Leech; D Fabbro; R A Stahel; U Zangemeister-Wittke Journal: Cancer Res Date: 2000-06-01 Impact factor: 12.701
Authors: S M Kennedy; L O'Driscoll; R Purcell; N Fitz-Simons; E W McDermott; A D Hill; N J O'Higgins; M Parkinson; R Linehan; M Clynes Journal: Br J Cancer Date: 2003-04-07 Impact factor: 7.640
Authors: Azeem Saleem; Julian C Matthews; Malcolm Ranson; Sophie Callies; Valérie André; Michael Lahn; Claire Dickinson; Christian Prenant; Gavin Brown; Adam McMahon; Denis C Talbot; Terry Jones; Patricia M Price Journal: Theranostics Date: 2011-06-01 Impact factor: 11.556